1. Context
    • Intellectual Property (IP) is a driving force of drug development at early stage. Identifying and patenting novel properties of HPH112, a known safe drug as a novel anticancer drug candidate
  2. Objectives
    • A promising safe “drug booster” available for fast and de-risked clinical development
  3. Solution
    • An appropriate oral formulation in oncology for patient compliance
  4. Results
    • Available for licensing out for development and commercialization
    • A strong IP position with patents already granted
    • Uses in combination with the most recent anticancer therapy – e.g anti-EGFR and immunotherapy